240 related articles for article (PubMed ID: 30986809)
1. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.
Billard-Sandu C; Tao YG; Sablin MP; Dumitrescu G; Billard D; Deutsch E
Eur Arch Otorhinolaryngol; 2020 May; 277(5):1273-1280. PubMed ID: 32162057
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
7. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
Kalu NN; Johnson FM
Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
[TBL] [Abstract][Full Text] [Related]
8. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
[TBL] [Abstract][Full Text] [Related]
9. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D
Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401
[TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; van Marcke C; Caignet X; Mendola A; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809148
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D; Bardia A; Sellers WR
Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
18. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
Fang H; Huang D; Yang F; Guan X
Breast Cancer Res Treat; 2018 Apr; 168(2):287-297. PubMed ID: 29236235
[TBL] [Abstract][Full Text] [Related]
20. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]